Interaction of ARC and Daxx: a novel endogenous target to

preserve motor function and cell loss after focal brain

ischemia in mice by Donath, Stefan et al.
Donath, Stefan and An, Junfeng and Lee, Sabrina Lin 
Lin and Gertz, Karen and Datwyler, Anna Lena and 
Harms, Ulrike and Müller, Susanne and Farr, Tracy D. 
and Füchtemeier, Martina and Lättig-Tünnemann, Gisela 
and Lips, Janet and Foddis, Marco and Mosch, Larissa 
and Bernard, Rene and Grittner, Ulrike and Balkaya, 
Mustafa and Kronenberg, Golo and Dirnagl, Ulrich and 
Endres, Matthias and Harms, Christoph (2016) 
Interaction of ARC and Daxx: a novel endogenous target 
to preserve motor function and cell loss after focal brain 
ischemia in mice. Journal of Neuroscience, 36 (31). pp. 
8132-8148. ISSN 1529-2401 
Access from the University of Nottingham repository: 
http://eprints.nottingham.ac.uk/35711/1/Donath2016JNeurosci36%208132-48%20full.pdf
Copyright and reuse: 
The Nottingham ePrints service makes this work by researchers of the University of 
Nottingham available open access under the following conditions.
This article is made available under the Creative Commons Attribution licence and may be 
reused according to the conditions of the licence.  For more details see: 
http://creativecommons.org/licenses/by/2.5/
A note on versions: 
The version presented here may differ from the published version or from the version of 
record. If you wish to cite this item you are advised to consult the publisher’s version. Please 
see the repository url above for details on accessing the published version and note that 
access may require a subscription.
For more information, please contact eprints@nottingham.ac.uk
Neurobiology of Disease
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Theaimof this studywas to explore the signaling andneuroprotective effect of transactivatorof transcription (TAT)protein transduction
of the apoptosis repressor with CARD (ARC) in in vitro and in vivomodels of cerebral ischemia inmice. Inmice, transient focal cerebral
ischemia reduced endogenousARCprotein inneurons in the ischemic striatumat early reperfusion timepoints, and inprimaryneuronal
cultures,RNA interference resulted ingreaterneuronal susceptibility tooxygenglucosedeprivation (OGD).TAT.ARCproteindelivery led
to a dose-dependent better survival after OGD. Infarct sizes 72 h after 60 min middle cerebral artery occlusion (MCAo) were on average
30 8% (mean SD; p 0.005; T2-weightedMRI) smaller in TAT.ARC-treatedmice (1g intraventricularly duringMCAo) compared
with controls. TAT.ARC-treated mice showed better performance in the pole test compared with TAT.-Gal-treated controls. Impor-
tantly, post-stroke treatment (3 h after MCAo) was still effective in affording reduced lesion volume by 20 7% (mean SD; p 0.05)
and better functional outcome comparedwith controls. Delayed treatment inmice subjected to 30minMCAo led to sustained neuropro-
tection and functional behavior benefits for at least 28 d. Functionally, TAT.ARC treatment inhibited DAXX–ASK1–JNK signaling in the
ischemic brain. ARC interacts with DAXX in a CARD-dependentmanner to block DAXX trafficking and ASK1–JNK activation. Our work
identifies for the first timeARC–DAXXbinding to blockASK1–JNKactivation as anARC-specific endogenousmechanism that interferes
with neuronal cell death and ischemic brain injury. Delayed delivery of TAT.ARCmay present a promising target for stroke therapy.
Keywords: behavioral outcome; brain ischemia; endogenousneuroprotection;middle cerebral artery occlusion; penumbra; TATprotein
transduction
Introduction
Stroke is a leading cause of death and disability worldwide (Saver
et al., 2009). For ischemic stroke, the only therapeutic options
that have proved to result in a better outcome are intravenous
thrombolysis, thrombectomy, hemicraniectomy, and stroke unit
care (Fisher and Saver, 2015; Moretti et al., 2015). Cerebral isch-
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Significance Statement
Uptonow,theonlysuccessfulpharmacologicaltargetofhumanischemicstrokeisthrombolysis.Neuroprotectivepharmacologicalstrategiesare
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emia initiates a cascade of pathological pathways that cause cell
death in the ischemic core within minutes after the onset of isch-
emia. Therefore, the aim of neuroprotective strategies is to inter-
rupt this cascade and stabilize metabolically compromised but
still viable brain cells in the ischemic penumbra. This concept
involves inhibition of pathological molecular events that eventu-
ally lead to the influx of calcium, oxidative stress, and neuronal
death (Broughton et al., 2009). Despite encouraging results from
animal experiments, clinical trials with neuroprotective therapies
have been unsuccessful until now. New therapeutic strategies are
needed.
Therapeutic approaches targeting neuronal cell death in
stroke must grapple with a complex challenge posed by multiple
signaling pathways, heterogenous mechanisms of cell death in
different subregions of the ischemic territory, and a limited time
window. Although damaged neurons often die from necrosis in
the core of the infarct, cerebral ischemia triggers two central path-
ways of apoptosis: the extrinsic or death receptor pathway and the
intrinsic or mitochondrial death pathway. Both result in the ac-
tivation of caspases that lead to the proteolytic destruction of the
cell (Namura et al., 1998; Broughton et al., 2009).Other upstream
modulators of apoptosis are mitogen-activated protein kinases
(MAPKs), JNK, ASK1, and DAXX (Wang et al., 1996; Kiriakidou
et al., 1997; Chang et al., 1998; Herdegen et al., 1998; Ko et al.,
2001; Irving and Bamford, 2002; Borsello et al., 2003; Kuan et
al., 2003; Putcha et al., 2003; Kuida and Boucher, 2004; Nishina et
al., 2004; Okuno et al., 2004; Gao et al., 2005; Salomoni and
Khelifi, 2006; Murata et al., 2012).
Apoptosis repressor with CARD (ARC) is a highly potent and
multifunctional inhibitor of apoptosis that is predominantly ex-
pressed in postmitotic cells, such as cardiomyocytes, skeletal
muscle cells, and neurons (Koseki et al., 1998). ARC was origi-
nally described as an inhibitor of the death receptor pathway
because it blocks apoptosis induced by a variety of death recep-
tors (CD95/FAS, TNFR1, and TRAMP/DR3) and their adaptors
(FADD and TRADD; Koseki et al., 1998). We recently showed
that ARC is able to block apoptosis induced by activators of the
mitochondrial death pathway such as ischemia/reperfusion in-
jury in the heart and doxorubicin-induced cardiotoxicity (Do-
nath et al., 2006; An et al., 2009). ARC inhibits both death
receptor and mitochondrial apoptotic death pathways through
nonhomotypic death-fold interactions. The death receptor path-
way is disrupted by interactions between ARC and FAS, FADD,
and procaspase-8 (Nam et al., 2004). The mitochondrial death
pathway is inhibited by ARC binding BAX (An et al., 2013). Fur-
thermore, treatment with exogenous ARC protein abrogates
TNF-mediated liver damage through the direct interaction of
ARCwith JNK1/2 and thus inhibits JNK-mediated TNF expres-
sion (An et al., 2012). Additionally, ARC protein transduction
interferes with the RIP pathway by inhibiting JNK1/2 activation
and counteracts acetaminophen overdose-induced hepatocellu-
lar necrosis (An et al., 2013).
Given ARCs multiple interactions in both apoptotic death
pathways, its interference with necrosis/programmed necrotic
cell death, and its comparably high protein expression in neu-
rons, we hypothesized that it could be acting like a toggle
switch between death and survival of neurons and thereby
constitute a novel therapeutic target. This led us to evaluate
the application of exogenous ARC protein in mice as a novel
stroke therapy.
Materials andMethods
All experimentswere conducted in an ISO9001-certified qualitymanage-
ment environment. Reporting of the study complies with the ARRIVE
(Animal Research: Reporting of In Vivo Experiments) guidelines (Kilk-
enny et al., 2010).
Primary neuronal cultures. Primary neuronal cultures were derived
from C57BL/6_N mice at embryonic day E16 as described previously
(Harms et al., 2004) and cultured with Neurobasal medium and B27
supplement (Invitrogen; Harms et al., 2007).
Oxygen glucose deprivation. Ischemic-like stress was induced in neuro-
nal cultures at day in vitro (DIV) 10 by combined oxygen glucose depri-
vation (OGD) for 150 min after treatment with transactivator of
transcription (TAT) proteins or if transduced with lentiviral particles for
loss of function.
Lactate dehydrogenase assay to assess cellular injury. Neuronal injury
after OGD was assessed by measuring lactate dehydrogenase (LDH) in
culture medium as described previously (Harms et al., 2004). Briefly,
LDHwasmeasured in culturemedium in a kinetic photometric assay (at
340 nm) at 24 h after the injury paradigm. Fifty microliters of culture
media were pipetted into 96-well plates and mixed with 200 l of
-nicotinamide adenine dinucleotide solution (0.15 mg/ml in 1 LDH
buffer). Measurement was started rapidly after addition of the reaction
substrate pyruvate (50 l of 22.7 mM pyruvate solution). Optical density
wasmeasured at 340 nmusing amicroplate reader, by 10 counts with 30 s
intervals, followed by calculation of results using an LDH standard
(Greiner; DiaSys). Themaximum release of LDHwas achieved by 20min
cell lysis with Triton X-100 as described recently, and data were normal-
ized to these measurements (Datwyler et al., 2011; Yildirim et al., 2014).
Propidium iodide incorporation. Cell viability was assessed after stain-
ing naive cell cultures with propidium iodide (PI) to distinguish between
living and dead cells (0.001 mg/ml for 5 min with subsequent rinsing),
and five images per well were taken using an inverted IX81 microscope
(Olympus) as described previously (Datwyler et al., 2011)with duplicates
per condition. Viable neurons not incorporating PI (PI) were counted
in transmission images and quantified as ratios versus all neurons as
described previously (Harms et al., 2007).
Lentiviral particle generation and transduction. Third-generation lentivi-
ral particles were used to express microRNA embedded small-hairpin RNAs
(shRNAs)targetingARC.Theywereproducedandtiteredusingenhancedgreen
fluorescentprotein (EGFP) expressionandwoodchuckposttranscriptional reg-
ulatoryelementasdescribedpreviously (Datwyleretal., 2011;Reichetal., 2011).
Loss-of-function experiments were performed using lentiviral transfer vectors
drivenbythesynapsinpromoter.Briefly,microRNA155embeddedcontroland
ARC target-specific shRNAs (miR-shRNA) were designed using the software
algorithmofBlock-iTRNAidesigner(Invitrogen)andblastedagainstthemouse
genome. Three different target regions in the 5UTR (TTGGCCCTTTCTG-
CACTGTCA), the open reading frame (ORF; AGCTATGACCCTTCATGC-
CCA), and the 3UTR (AGTCTTGGCGCTCACAGTCTT) of Nol3/ARC
(National Center for Biotechnology Information nucleotide accession number
NM_030152.4) were used to design oligonucleotides for oligo annealing and
ligation into pcDNA6.2-GW/EmGFP-miR (Invitrogen) with the following se-
quences: NM_030152.4 (Nol3, ARC)_5UTR_8, TGCTGTGACAGTGCAG
AAAGGGCCAAGTTTTGGCCACTGACTGACTTGGCCCTCTGCACT-
GTCA; NM_030152.4_ORF_479, TGCTGTGGGCATGAAGGGTCATA
GCTGTTTTGGCCACTGACTGACAGCTATGACTTCATGCCCA; and
editing assistance. pTAT.HA and pTAT.-Gal were kindly provided by S. Dowdy (Howard Hughes Medical
Institute, La Jolla, CA).
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NM_030152.4_3UTR_1271, TGCTGAAGACTGTGAGCGCCAAGAC
TGTTTTGGCCACTGACTGACAGTCTTGGCTCACAGTCTT.
The nontargeting negative control miR-shRNA (scrambled) was
TGCTGAAATGTACTGCGCGTGGAGACGTTTTGGCCACTGACTG
ACGTCTCCACGCAGTACATTT.
These miR-shRNAs with an EGFP reporter were subcloned into a
modified derivate of Addgene plasmid 27232 driven by a neuron-specific
RNA polymerase II-dependent synapsin promoter as described previ-
ously (Datwyler et al., 2011). Neuronal cultures were transduced on DIV
3. After 96 h, transduction efficiencies (95%of neurons) andmultiplic-
ity of infection (	5) were determined and calculated from serial dilu-
tions in neuronal cultures using EGFP fluorescence as a reporter. Three
different ARCmiR-shRNAs were tested for knockdown efficacy; the best
candidate was used for additional analysis (miR-shRNA_ARC_8_5UTR) and
comparedwith controlmiR-shRNA.
Immunoblotting and immunoprecipitation. Brains were cut in three
sagittal slices from median to lateral and collected for each hemi-
sphere. Protein extracts were prepared and subjected to either SDS
page and immunoblot analysis or immunoprecipitations as previ-
ously described (Hauck et al., 2007, 2008; An et al., 2012, 2013). For
immunoprecipitation, protein extracts were mixed with antibodies
(1–5 g/ml) for 2 h on a rotating wheel. This was followed by the
addition of 50 l of protein A or G Plus-Sepharose beads (Roche) or
30 l of agarose conjugated JNK1 (sc-1648 AC)/JNK2 (sc-827 AC) or
phospho-SAPK/JNK (Thr183/Tyr185) beads for 1 additional hour at
4°C. Immunoprecipitates were washed four times with RIPA buffer
[for activated Bax, we used CHAPS buffer as described (Gustafsson et
al., 2004)] and boiled in 50 l of SDS sample buffer. Samples were
resolved over 12 or 15% SDS-polyacrylamide gels and transferred onto
nitrocellulose membranes. The membrane was probed with primary
antibodies and then incubated with the secondary antibody (1:2500 di-
lution). Immunocomplexes were detected using the enhanced chemilu-
minescence system (GE Healthcare). Anti-ARC (1:2000 dilution) was
purchased from ProSci. Anti-Actin (1:2000 dilution) was obtained from
Calbiochem. Anti-caspase-8 antibody (1:1000 dilution) was obtained
from Alexis Biochemicals. phospho-ASK1 (S967, 1:500 dilution),
phospho-ASK1 (T845, 1:500 dilution), anti-caspase-3 antibody (1:1000
dilution), anti-caspase-9 antibody (1:1000 dilution), anti-phospho-c-
Jun (P-c-Jun; 1:1000 dilution), anti-c-Jun (c-Jun, 1:1000 dilution), anti-
Daxx (1:500), anti-JNK2 (1:1000 dilution), anti-JNK3 (1:1000 dilution),
anti-phospho-JNK (Thr183/Tyr185; P-JNK, 1:1000 dilution), phospho-
SAPK/JNK (Thr183/Tyr185; 81E11; Sepharose Bead Conjugate), anti-
phospho-p44/42 MAPK (P-p44/42; 1:2000 dilution), and anti-p44/42
MAPK (p44/42, 1:1000 dilution) were purchased from Cell Signaling
Technology. Anti-Bax (1:1000 dilution), anti-HA tag (1:1000 dilution),
anti-JNK2, agarose conjugated JNK1 (sc-1648 AC), JNK2 (sc-827 AC),
and anti-JNK (JNK, 1:1000 dilution) were purchased from Santa Cruz
Biotechnology. Anti-Bax6A7 (1:1000 dilution) and anti-JNK1 (1:1000
dilution) were obtained from BD Pharmingen. Anti-His tag (1:1000 di-
lution) and anti-phospho-JNK (Thr183/Tyr185; P-JNK, 1:1000 dilu-
tion) were purchased from Invitrogen. Anti-Bim (1:1000 dilution) was
obtained from Stressgen. Anti-ASK1 (1:1000 dilution) and anti-HA-Tag
(1:4000 dilution) were purchased from Abcam. Anti-JNK, HRP conju-
gates was obtained from Abcam. Protein A Sepharose beads for rabbit
antibody and Protein G beads for mouse IgG1 were obtained from
Roche. HRP-conjugated secondary antibody specific for mouse IgG
and specific for rabbit IgG was from GE Healthcare (1:2500 dilution).
All other chemicals were purchased from standard commercial
sources.
Densitometry of immunoblots. Western blot quantification were per-
formed after smart background subtraction (rolling ball algorithm) us-
ing NIH ImageJ, and each band was normalized to the total gray
intensities of a given blot and expressed as the ratio to the housekeeping.
Each red spot represents immunoblots of individual animals/time
points. Adjustment of densitometric measures to the lesion was done on
magnetic resonance imaging (MRI)-based T2 lesion volume per slice,
and a dilution factor with non-T2-enhanced “healthy” brain tissue was
used to adjust for immunoblot signals derived from a specific stroke
subregion.
TAT fusion proteins. For the generation of recombinant proteins,
pTAT.HA and pTAT.-Gal vectors were obtained fromS.Dowdy (How-
ard Hughes Medical Institute, La Jolla, CA). We produced TAT recom-
binant proteins as published previously (Hauck et al., 2007, 2008; An et
al., 2012, 2013). A scheme of all TAT protein constructs is shown in
Figure 6D. Protein purity was evaluated by SDS-PAGE and Coomassie
blue staining. Concentrations of the purified proteins were determined
by the Bradford method and adjusted to 1g/l with bovine albumin as
a standard (Pierce, Thermo Fisher Scientific).
Middle cerebral artery occlusion and TAT protein delivery. Filamentous
middle cerebral artery occlusion was performed for 60 min with indi-
cated reperfusion time points according to the protocol published as a
Standard Operating Procedure (SOP) protocol by Dirnagl et al. (doi:
10.1038/npre.2010.3492.2). In addition, 30 min middle cerebral artery
occlusion (MCAo) was performed with a 28 d observation period to
corroborate sustainability of the neuroprotective and neurorestorative
effects (Fig. 8). All animal experiments were approved by the Berlin
governmental authorities (Landesamt fu¨r Gesundtheit und Soziales,
G0385/08 and G197/12). Male C57BL/6NCrl mice were derived from
Charles River at the age of 8 weeks and were used in the experiments at
the age of 10–12 weeks. All animals had access to food and water ad
libitum andwere kept under a 12 h light/dark cycle. No specific exclusion
criteria were set. Onemouse was excluded because it showed no lesion in
the MRI or a functional deficit in the first setting of in vivo experiments
(see Fig. 2). Table 1 lists the survival and time of death events in detail.
TAT protein delivery in the contralateral ventricle. TAT proteins were
delivered by stereotaxic inoculation in the lateral ventricle of the con-
tralateral hemisphere with injection over 5 min starting 15 min after
MCAo and a total volume of 1 l with 1 g of highly purified recombi-
nant TAT-fusion proteins with the following coordinates: 0.7mmcaudal
to bregma, 1.3 mm lateral to sagittal suture (right side), and 1.3 mm in
depth. The needle was retracted carefully within 5min. In case of delayed
treatment, a total volume of 5 l was injected with 5 g of protein of the
respective TAT protein.
MRI. MRI was performed using a 7 Tesla rodent scanner (Bruker
Pharmascan 70/16AS) with a 16 cm horizontal bore magnet and a 9 cm
(inner diameter) shielded gradientwith anH-resonance frequency of 300
MHz and a maximum gradient strength of 300 mT/m. For imaging, a
1-hydrogenproton radio frequency quadratur-volume resonatorwith an
inner diameter of 20 mm was used. Data acquisition and image process-
ing were performed with the Bruker software Paravision 4.0. During the
examinations, mice were placed on a heated circulating water blanket to
ensure constant body temperature of 37°C. Anesthesia was induced with
2.5% and maintained with 1.0–2.0% isoflurane delivered in a O2/N2O
mixture (30/70%) via a facemask under constant ventilationmonitoring.
Table 1. Survival data of 145 animals
Animals
(n)
MCAo
length (min)
TAT.application:
Time/dose
TAT.-Gal–sham:
n/death event (day)
TAT.-Gal–MCAo:
n/death event (day)
TAT.ARC–sham:
n/death event (day)
TAT.ARC–MCAo:
n/death event (day)
Number of animals
at survival endpoint Data shown
24 60 During MCAo 
1g — 12/1 (1); — 12/0 (n/a) 23/3 d Figs. 2, 3, 5, 6
30 60 3 h post MCAo 
5g — 15/0 (n/a) — 15/1a (1) 29/3 d Fig. 7
40 60 During MCAo 
1g 5/0 (n/a) 15/0 (n/a) 5/0 (n/a) 15/0 (n/a) 40/3–24 h Figs. 4, 6
5 n/a TAT.ARCL31F/G69R — — 5/0 (n/a) — 5/24 h Fig. 6
46 30 3 h post MCAo 
5g 8/0 (n/a) 15/1 (7) 8/0 (n/a) 15/4 (1, 7, 8, 10) 41/28 db Fig. 8
aSurvival was tested with the log-rank Mantel–Cox test with2 6.081 (df 3) and p 0.11 indicative that survival did not differ between groups in the last experiment.
bAnimal died after MCAo before TAT.application.
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A rapid acquisition with relaxation enhancement (RARE) T2-weighted
sequence was used. Imaging parameters were as follows: for T2, repeti-
tion time, 4200; echo time, 36ms; RARE factor 8, 4 averages. Twenty axial
slices with a slice thickness of 0.5 mm, a field of view of 2.75 2.75 cm,
and a matrix of 256 256 were positioned over the brain excluding the
olfactory bulb.
Stroke volume and regional stroke volume in 2mm sagittal slices used
for the biochemical assays were analyzed using Analyze 5.0 and NIH
ImageJ software. For stroke volumetry, hyperintense areas of ischemic
tissue in T2-weighted images were assigned with a region of interest tool.
This enabled a threshold-based segmentation that was performed by
connecting all pixels within a specified threshold range around the se-
lected seed pixel and resulted in a 3D object map of the whole stroke
region. The total volume of the whole object map was calculated
automatically.
To calculate the regional ischemic lesion volumes that would corre-
spond to slices prepared for immunoblots, axialMR images were divided
with NIH ImageJ into three equal slices from medial to lateral. The vol-
umes of hyperintense areas in each brain section were calculated by An-
alyze 5.0 as described above. Brain parenchyma were cropped for
presentation purposes.
Pole test. The pole test was performed to analyze sensorymotor function.
The test was performed in a blindedmanner with treatment allocation con-
cealed throughout. Mice were habituated to the procedure the day before
testing. They were placed head upward near the top of a vertical rough-
surfacedpole (1cmdiameter, 50cmheight) and thenallowed todescend five
times during one experimental session. The total time needed to turn com-
pletely head downward (“time-to-turn”) and the time it took the mouse to
reach the floor with all four paws (“time-to-come-down”) were recorded.
Criteria for inclusion of mice for evaluation in the pole test were a non-
interrupted “smooth” run tomeasure the time-to-descend and an immedi-
ate initiation to turnwithno additional interruption to comedown thepole.
Because of this criteria, we had to exclude five animals in the TAT.-Gal-
treated group and three animals in the TAT.ARC-treated group in the de-
layed application series (see Fig. 7).
Modified DeSimoni neuroscores, rotarod test, and non-invasive body
temperature measures. DeSimoni neuroscore was performed at the indi-
cated time points (see Fig. 8) as described previously (De Simoni et al.,
2003; Orsini et al., 2012) with some modifications. In brief, general
health (Table 2) and specific focal assessments (Table 3) were separately
scored, analyzed, and finally added to form a summation score. Summa-
tive scores added up to a maximum of 43 points, with more points
meaning more deficits.
Rotarod was assessed as described recently (Hoffmann et al., 2015),
and the best run of three replicates at a given time point was used for
statistical analysis.
Body temperature was non-invasively assessed at the same time of the
day before body weightmeasurements using subcutaneous transponders
(IPTT-300; Bio Medic Data Systems) for unambiguous identification of
mice in their home cages as described previously (Kort et al., 1998;
Langer and Fietz, 2014).
Coronal sections and mouse brain coordinates for histology. Mouse
brains were cut in coronal sections using a mouse brain atlas (Franklin
and Paxinos, 2007) to analyze direct and indirect infarct volumes (a1–a5,
area), striatal area, and neuronal densities within the striatum were de-
termined in a3. a1 interaural 6.6 mm/bregma 2.80; a2 interaural
5.34 mm/bregma 1.54; a3 interaural 3.94 mm/bregma 0.14; a4
interaural 1.86 mm/bregma  1.94; a5  interaural 0.08 mm/
bregma3.88.
Histology. Immunohistochemistry for Figure 1A was performed in
paraffin-embedded 4-m-thick coronal sections after perfusion with
physiological saline and 4%paraformaldehyde (PFA) in deep anesthesia.
Rabbit anti-ARC antibody (F100) and mouse anti-NeuN (F100) were
incubated overnight after blocking with 10% normal donkey serum in
0.1%Triton X-100. Secondary antibodies were derived from donkey and
conjugated to Rhodamine Red X (anti-rabbit) or FITC (anti-mouse).
Sections were mounted in Immunomount Gold (Invitrogen) and visu-
alized using confocal microscopy. Immunohistochemistry, hematoxylin
staining, and histology were performed as described previously (Reich et
al., 2011). Neuronal densities were achieved by anti-NeuNDAB staining
as described previously (Hoffmann et al., 2015).
Imaging acquisition and quantification of neuronal densities. Image col-
lection of NeuN–DAB-stained brain slices from mice 28 d after MCAo
were collected as transmission images using a Leica DMI8 microscope
equipped with an LED light source, a Fluotar 10/030 dry objective, and
a DFC300G camera and stitched within the Leica LAS X2.0 software.
Striatal neuronal areas were measured from coronal section three (a3)
directly, and NeuN-positive cell counts were derived from thresholded
and segmented images in the public domain program NIH ImageJ. Di-
rect lesion volumes were calculated from five coronal brain sections as
described previously (Hoffmann et al., 2015).
Statistical analysis. Our study was designed as an exploratory analysis
of the endogenous neuroprotective mechanisms of ARC as a potential
therapeutic target (Kimmelman et al., 2014). The first part of our study
(see Figs. 1-7) uses post hoc tests (e.g., Tukey’s test) to correct formultiple
testing for each figure separately. The second part of our study (see Fig. 8)
focuses on sustained effects of TAT.ARC treatment in MCAo mice with
28 d survival, and we used five hypotheses with hierarchical testing. All
data are presented as means and scattered dot plots  SEM. We calcu-
lated 95% confidence intervals (CIs) for Figure 8, F, L, and M, and
presented all animals with box and whiskers for Figure 8K. Two-way
repeated-measures (RM) ANOVA with Bonferroni’s post hoc tests for
Table 2. Modified DeSimoni neuroscore for the assessment of general deficits
No.
General versus
focal deficits Objective Assessment/instruction Score 0 Score 1 Score 2 Score 3 Score 4 Summative score
1 General deficits Hair Mouse observed on open bench top
(OS). Observation with no
interference
Hair neat and clean Lack of grooming, piloerection
and dirt on the fur around
nose and eyes
Lack of grooming, piloerection,
and dirty coat, extending
beyond just nose and eyes
0–2
2 General deficits Ears Mouse on OS. Observation at the
beginning with no interference
and then stimulation by click-
ing one’s tongue
Normal. Ears are stretched laterally
and behind. They react by
straightening up after noise
Stretched laterally but not
behind (one or both).
They react to noise
Same as 1. They do not react to
noise
0–2
3 General deficits Eyes Mouse on OS. Observation with no
interference or stimulation
Open and clear (no discharge) Open and characterized by
milky white mucus
Open and characterized by
milky dark mucus
Eyes clotted (one or both
sides)
Closed 0–4
4 General deficits Posture Place the mouse on the palm of
your hand and rock gently to
observe stability
The mouse stands in the upright
position on four limbs with the
back parallel to the palm.
During the rocking movement,
it uses its limbs to stabilize
itself
The mouse stands hump-
backed. During the rock-
ing movement, it lowers
its body instead of using
its limbs to gain stability
The head or part of the trunk
lies on the palm
The mouse reclines to one side
but may be able to turn to
an upright position with
some difficulty
No upright position
possible
0–4
5 General deficits Spontaneous Activity Mouse on OS. Observation with no
interference or stimulation
The mouse is alert and explores
actively
The mouse seems alert, but it
is calm and quiet
The mouse starts and stops
exploring repeatedly and
slowly. The mouse is list-
less, moves sluggishly but
does not explore
The mouse is lethargic or
stuporous and barely
moves during the 60 s
No spontaneous
movements
0–4
0–16
Donath et al. • TAT.ARC and Cerebral Ischemia J. Neurosci., August 3, 2016 • 36(31):8132–8148 • 8135
comparison of simple treatment effects within control or OGDwas used
for Figure 1D. Two-way ANOVA with Tukey’s post hoc analysis was
performed for miR-shRNA effects on OGD and TAT protein transduc-
tion of neuronal cultures (Fig. 1H ). Two-way RM ANOVA, followed by
Tukey’s post hoc analysis, was performed for MRI stroke volume assess-
ment after 24 and 72 h (see Fig. 2C). Two separate mixed linear models
were performed for sagittal slice-specific MRI stroke volume assessment
for 24 and 72 h Sidak’s post hoc tests (see Fig. 3A), including treatment
and slice area as covariates. Mann–Whitney U rank-sum test was per-
formed for behavioral analysis and stroke volume analysis (pole test; Figs.
2E, 7B, histology,C). Two-tailed Student’s t test was performed for direct
stroke volume analysis after 28 d and for testing differences in ratios of
counted NeuN-positive cells within the striatum (coronal slice a3; see
Fig. 8L,M ). The number of experimental units required to detect a stan-
dardized effect size0.25 was calculated by a priori power analysis with
the following assumptions: 0.05; 0.2;mean, SD 20%of themean
for in vivoMCAo experiments.
Seven separate linear mixed models were used to analyze total neuro-
score values (see Fig. 8B), general neuroscore values (see Fig. 8C), focal
deficit values (see Fig. 8D), rotarod values (see Fig. 8E,F ), striatal area
per hemisphere in coronal slice a3 (see Fig. 8K ), body weight (see Fig.
8G), and body temperature (dependent variables; see Fig. 8H ) to test
differences between TAT.ARC and -Gal within sham and MCAo mice
(random intercept models to account for average differences in outcome
betweenmice and clustered data structure). To analyze the rotarod data,
we used the best value of three measures for each time point and each
animal. Main hypotheses were related to differences between TAT.ARC-
and -Gal-treated mice with MCAo. Specifically, we tested five hierar-
chical ordered main hypotheses [hypothesis 1, differences in MCAo
group between TAT.ARC- and -Gal-treated mice in the general neuro-
score; hypothesis 2, same as in 1 but focal score; hypothesis 3, same as in
1 but sustainability of neuroprotection by TAT.ARC in MCAo mice
compared with -Gal-treated mice as shown by rotarod values at 14 d;
hypothesis 4, morphological correlates presenting less striatal atrophy by
TAT treatment (compared to -Gal-treated mice) within MCAo; and
hypothesis 5, smaller direct lesion volume or lower number of NeuN-
positive neurons within the striatum] by using a hierarchical test proce-
dure to control the familywise error rate for these subanalyses. For these
hierarchical testing, a two-sided significance level of   0.05 was con-
sidered. All additional hypotheses were tested exploratory. For the linear
mixed regressionmodels, we used all available measures over time for all
mice (255 measures for 45 mice for the total neuroscore/general neuro-
score/focal deficit; 128measures for 45mice for rotarod, 62measures for
31 mice for striatal area in a3, 1173 measures for 46 mice for body tem-
perature/body weight). As independent variables, we included the group
(sham orMCAo), the intervention (TAT.ARC or -GAL), and the inter-
action between group and intervention in all models. For the models for
neuroscore values (total, general, and focal deficit), for the rotarod data,
and for body temperature and body weight, we additionally included
time (day centered and for the neuroscore models as well as for body
temperature and body weight additionally, a squared term for time to
account for the curvilinear relation between time and the dependent
variable) and the interaction terms group time and intervention
time. For the two-lesion volume model, we included the information
on hemisphere (ipsilateral or contralesional) and the interaction be-
tween group hemisphere and intervention hemisphere. In case of
skewed distribution of outcome, we transformed the values before
regression. All reported p values are related to post hoc tests from the
mixed models. Differences in survival rates were calculated by the
log-rank test (Table 1).
Methods to prevent bias.Cell counts for survival of neurons that are not
incorporating propidium iodide (PI) were performed after blinding,
Table 3. Modified DeSimoni neuroscore for the assessment of focal deficits
No.
General
versus focal
deficits Objective Assessment/instruction Score 0 Score 1 Score 2 Score 3 Score 4
Summative
score
6 Focal deficits Body symmetry Mouse on OS, observation of undis-
turbed resting behaviour and
description of the virtual nose–
tail line
Normal. a, Body: normal posture,
trunk elevated from the bench,
with forelimbs and hindlimbs
leaning beneath the body. b,
Tail: straight
Slight asymmetry. a, Body:
leans on one side with
forelimbs and hindlimbs
leaning beneath the body.
b, Tail: slightly bent
Moderate asymmetry. a, Body:
leans on one side with
forelimbs and hindlimbs
stretched out. b, Tail:
slightly bent
Clear asymmetry. a, Body
leans on one. b, Tail:
clearly bent
Complete asymmetry. a,
Body. b, Tail
0– 4
7 Focal deficits Gait Mouse on OS. Observation of undis-
turbed movements
Normal. Gait is flexible, symmetric,
and quick
Stiff, inflexible. The mouse
walks humpbacked,
slower than normal mice
Limping with asymmetric
movements
More severe limping, drifting,
falling with obvious defi-
ciency in gait
Does not walk spontaneously.
(In this case, stimulation
will be performed gently
pushing the mouse with
a pen. When stimulated,
the mouse walks no
longer than three steps.)
0– 4
8 Focal deficits Climbing Mouse is placed in the center of a
gripping surface at an angle of
45° to OS
Normal. The mouse climbs quickly Climbs slowly, limb weakness
present
Holds onto slope, does not slip
or climb
Slides down slope; difficulty to
prevent fall
Slides down slope, unsuccess-
ful effort to prevent fall
0– 4
9 Focal deficits Circling behavior Mouse on OS. Observation of the
mouse walking undisturbed on
the OS
Circling behavior absent. The
mouse turns equally to left or
right
Predominantly one-sided
turns. Optional: record to
which side the mouse
turns
Circles to one side, although
not constantly
Circles constantly to one side.
This one is now high-
lighted in yellow
No movements 0–4
10 Focal deficits Forelimb symmetry Mouse suspended by the tail.
Movements and position of
forelimbs are observed
Normal. Both forelimbs are ex-
tended towards the bench and
move actively
Light asymmetry. Contralat-
eral forelimb does not
extend entirely
Marked asymmetry. Contralat-
eral forelimb bends to-
wards the trunk. The body
slightly bends on the side
ipsilateral to the stroke
Prominent asymmetry. Con-
tralateral forelimb ad-
heres to the trunk
Slight asymmetry, no body/
limb movement
0–4
11 Focal deficits Compulsory circling Forelimbs on bench, hindlimbs
suspended by the tail. This
position reveals the presence of
the contralateral limb palsy. In
this handstand position, limb
weakness is displayed by a
circling behavior when the
animal attempts forward mo-
tion
Absent. Normal extension of both
forelimbs
Both forelimbs extended but
begins to circle predomi-
nantly to one side
Circles only to one side and
may fall to one side
Pivots to one side sluggishly
and does not rotate in a
full circle. Mouse will fall
to one side
No or rare movements 0–4
12 Focal deficits Gripping of the fore-
paw
Mouse is held by the tail on the
wire bar cage lid, so that the
forepaws touch the grid
Mouse grasps the grid firmly with
forepaws and tries to place the
hind paws also onto the grid
by pulling the hindpaws under
the body
Mouse accesses the grid but
has less power. A slight
pull breaks the grip of the
forepaws
Mouse cannot grip with the
impaired forepaw
Mouse cannot grip the grid 0–3
0–27
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randomization, and blinding of the allocation to treatment groups. Ten
high-power fields derived from duplicate wells per experiment was used
to calculate the mean that was further analyzed as an independent data
point. A total of four independent cell culture platingswere used, and 689
and 780 cells in control conditions and after OGDwere analyzed overall.
Survival and the number of 145 animals allocated to the various
groups and finally evaluated are described in Table 1. Twelve mice per
group (in 24 mice) were used for Figure 2, but one animal died and one
animal was excluded before analysis and unblinding to the groups be-
cause it had no visible stroke (both from the TAT.-Gal group). Thirty
mice were used for the delayed treatment protocol in Figure 7 (15 per
group). Onemouse died from the TAT.ARC-treated group. Ten animals
were subjected to sham surgery and received TAT.-Gal or TAT.ARC
(each five animals), and 30 animals were transduced with TAT proteins
andwere subjected to 60min ofMCAowith 3, 8, or 24 h reperfusion time
(each 5 animals) for immunoblots in Figures 3B, 4,A andB, 5, and 6,A–C
and E. An additional five animals were transduced with TAT.ARC.mu-
tant (see Fig. 6E). No animals died or had no lesion in the time course
study. In summary, of the 145 animals, 137 animals were included in the
study and reached the endpoint. Survival in the 28 d sustained neuropro-
tection study (see Fig. 8) is documented in detail in Table 1, and no
animals were excluded in this substudy. The experimental outlines are
depicted in Figures 2, 7, and 8 and Table 1.
Animals were randomized using the GraphPad calculator tool (http://
graphpad.com/quickcalcs/randomize1/) before the experiments by a sci-
entist who was not involved in the surgery, the TAT application, or
behavioral or MRI analysis. All details on cage number, group of surgery
cohort (day), and mouse identification can be found in the open data
resources that are available for this publication on Figshare Repository
and that are described under original data deposition. Concealment of
treatment allocation was maintained throughout the study. The surgeon
was blinded for the grouping to either the control or the TAT.ARC pro-
tein. MRI analysis was performed by a computer-aided algorithm by
scientists who were not involved in surgery, TAT application, or behav-
ioral analysis, and both the grouping and the treatment allocation were
concealed for stroke volume analysis and behavioral tests. The specific
inclusion criteria for the pole test were set before the experiment.
Criteria for inclusion of mice for evaluation in the pole test were a
non-interrupted smooth run to measure the time-to-descend and an
immediate initiation to turn with no additional interruption to come
down the pole. Because of these criteria, we had to exclude five animals in
the TAT.-Gal-treated group and three animals in the TAT.ARC-treated
group in the delayed application series (see Fig. 7).
Original data deposition. The following primary datasets, MRI scans,
original behavioral datasets, histological analyses, or stitched histology
images of NeuN are available as open data on Figshare Repository in raw
data format: Figure 1, C and D, cell counts, https://doi.org/10.6084/m9.
figshare.3405787 (Donath et al., 2016a); Figure 1 H, normalized
LDH data, https://doi.org/10.6084/m9.figshare.3406282 (Donath et al.,
2016h); Figures 2 and 3, MRI original data, https://doi.org/10.6084/m9.
figshare.3398722 (Donath et al., 2016g); Figure 3A, MRI slice results of
T2 lesion after 24 and 72 h, https://doi.org/10.6084/m9.figshare. 3 4 2 0 8 8 3
(Donath et al., 2016f); Figure 7C, histology of infarct volumes, https://doi.
org/10.6084/m9.figshare.3420868 (Donath et al., 2016e); Figure 8A–H, be-
havior, body weight, and body temperature, https://doi.org/10. 6084/m9.
figshare.3420901 (Donath et al., 2016d); Figure 8K--M, striatal volume,
chronic lesion volume, and striatal neuronal cell counts, https://doi.
org/10.6084/m9.figshare.3398761 (Donath et al., 2016c); and Figure 8,
I and J,NeuN-DAB_stainings_in_sham_MCAo_mice_with_28-days_survival,
https://doi.org/10.6084/m9.figshare.3413683 (Donath et al., 2016b).
Results
Endogenous and exogenous ARC provides neuroprotection
against OGD
We identified an early loss of ARC protein in neurons in the
ischemic striatum at 20 h of reperfusion after MCAo in vivo (Fig.
1A). We corroborated loss of ARC protein byWestern blot anal-
ysis of the ischemic striatal core after 3, 8, and 24 h of 60 min of
transient MCAo with a gradual decrease over time (Fig. 1B).
Next, we investigated whether increasing ARC protein levels us-
ing TAT.ARC protein transduction would provide neuroprotec-
tion. We tested neuronal cultures and applied TAT proteins 1 h
before OGD (Fig. 1C,D). Exogenous ARC protein provided
strong, dose-dependent neuroprotection that was similar to and
not significantly different from control cultures (Fig. 1D). To inves-
tigate whether endogenous ARChad an effect on neuronal vulnera-
bility, we used RNA interference to gradually reduce ARC protein
content in primary neuronal cultures (Fig. 1E,F,H). Lentiviral
particles coding for a scrambled microRNA-embedded shRNA
(control-shRNA) served as a control. shRNAs were driven by a
neuron-specific synapsin promoter. EGFP was used to serve as a
reporter for bicistronic expression of miR-shRNA. Although the
baseline number of neuronal cells did not vary, neurons with re-
duced ARC protein levels were more vulnerable and prone to neu-
ronal cell loss after combined OGD (Fig. 1F,H). We aimed to
directly compare the effects of gain and loss of function and applied
themost effective dose derived from titration experiments (Fig. 1D)
and thecorrespondingTAT.-Gal control and lentiviralparticles for
RNAinterference inone set andperformed four independent exper-
iments with 150min of OGD (Fig. 1F–H).
TAT.ARC protein transduction protects mice from transient
focal cerebral ischemia
Weexposedmice toMCAo, applied TATproteins intracerebroven-
tricularly, and analyzed several time points of reperfusion. The ex-
perimental setup is shown in detail in Figure 2A. We tested the
distribution of TAT.-Gal or TAT.ARC in the brain and their pro-
tein stability in the ischemic territory over time in Figure 2,B andC.
The ipsilateral hemispheres were cut in three 2-mm-thick sagittal
slices to demonstrate the spread of the proteins in brain lysates of
these subregions after contralateral intrathecal TAT protein admin-
istration 72 h after 60 min MCAo (Fig. 2B). Both TAT.-Gal and
TAT.ARC showed lower immunoreactive protein on the same im-
munoblot membrane over time when we compared their presence
in the ischemic core at 3, 8, and 24 h of reperfusion (Fig. 2C).
TAT.ARC-treated mice showed infarct sizes that were significantly
smaller than those with TAT.-Gal-treated controls 72 h after 60
minMCAo byMRImeasurement (Fig. 2D,E). This was confirmed
by histological analysis at 72 h (Fig. 2F). In the cortical subregion of
the ischemic territory,MRIhadalready revealeddifferences in lesion
volume between treatment groups at 24 h (Fig. 3A), indicative of a
protective effect of TAT.ARC treatment in the penumbra. This re-
duction in the cortical penumbrawasmore pronounced at 72 h and
resulted in a significantly smaller entire ischemic territory in
TAT.ARC-treated mice (Fig. 3A). This lower lesion volume after
MCAo was associated with significantly better behavioral function
compared with control animals (Fig. 2G).
In analogy to the biochemical analysis, in which brains were
cut in three sagittal slices frommedial to lateral and collected for
each hemisphere, we cut/separated the brain MRI scans into
slices that corresponded to cortical penumbra (lateral), ischemic
core (middle), and striatal penumbra (medial) and analyzed le-
sion volumes for each slice (see Materials and Methods and Fig.
3A). We performed this type of analysis because smaller lesion
volumes in the treatment group and differing pathophysiological
processes in the core and the penumbra of the ischemic territory
may confound the analysis of the mechanisms underlying the
neuroprotective effect of ARC.
MRI-based regional subgroup analysis of lesion volumes
showed significant effects of TAT protein delivery on the cortical
penumbra after 24 and 72 h of reperfusion (Fig. 3A), whereas the
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Figure 1. ARC is expressed in neurons and serves as an endogenous and exogenous neuroprotective protein against OGD.A, C57BL/6micewere subjected to 30min ofMCAo or shamprocedure.
PFA and paraffin-embedded 4m sections were stained for ARC protein (Rhodamine Red X) and neuronal counterstain with NeuN (FITC) after 20 h of reperfusion. Microscopic pictures were taken
witha confocalmicroscope. Scalebar, 50m.B, C57BL/6micewere subjected to60minofMCAo, and the striatal ischemic corewas isolatedat indicated timepoints. Immunoblots forARCandACTIN
protein was performed from brain lysates and densitometric analysis [n 3 animals (red dot plots and mean SEM), ordinary ANOVA and Tukey’s post hoc test]. C, D, Exogenous ARC protein
transduction leads to a dose-dependent increase in neuronal survival after OGD comparedwith TAT.-Gal-treated neurons. F[Degrees of freedom for the numerator: DFn, Degrees of freedom for the
denominator: DFd](4,30) 3.858with p 0.0121 for TAT treatmentOGD interaction and F[DFn, DFd](4,30) 64.28with p 0.0001 for effects of OGD. Datawere derived from four independent
experiments and shown as red dot plots, whereas bars were presented as mean  SEM. Primary neuronal cultures were transduced with lentiviral particles for (Figure legend continues.)
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ischemic core and medial striatum showed no significant differ-
ence between TAT.-Gal- and TAT.ARC-treated mice at either
reperfusion time point (Fig. 3A).
Exogenous ARC prevents cleavage of caspase-8, caspase-9,
and caspase-3 and prevents activation of BH3-only proteins
BAX/ BIM and JNK pathways
Brain sections were analyzed by immunoblots and showed sub-
stantially less activation of caspase-8, caspase-9, and caspase-3 in
all subregions of the ischemic brains treated with TAT.ARC pro-
teins compared with the TAT.-Gal-treated animals (Fig. 3B
with semiquantitative analysis non-adjusted and adjusted to the
lesion volume in a given slice in C). Although the proapoptotic
BH3-only protein BAX was strongly activated in TAT.-Gal-
treated animals after MCAo, only weak BAX activation was de-
tected in the ARC-treated group (Fig. 3B,C). Furthermore,
phosphorylation of JNK isoforms was lower in case of exogenous
ARC protein delivery, whereas total JNK1-3 protein expression
was not different (Fig. 3D,E). In turn, this completely blocked
BIM phosphorylation at serine 69, because it depends on JNK
activity (Fig. 3F,G). Together, both initiator and effector
caspases of the extrinsic and intrinsic apoptotic death pathway, as
well as initiator and effector targets of the JNK signaling pathway
were attenuated by TAT.ARC protein transduction at 72 h of
reperfusion.
TAT.ARC inhibits DAXX–ASK1–MKK–JNK signaling after
focal ischemia
We observed less activation of JNK at 72 h of reperfusion and
therefore analyzed the time course of upstream DAXX, ASK1,
and JNK signaling in ischemic brains (Fig. 4A,B). We subjected
five animals per group to 60 min MCAo with TAT.-Gal or
TAT.ARC treatment and indicated time points of reperfusion
and analyzed the core ischemic region and corresponding con-
tralateral section with immunoblotting. Lesion size did not differ
significantly in this section (Fig. 3A). By so doing, we accounted
for the fact that any differences seen in TAT.-Gal- or TAT.ARC-
treated animals in the assays may be a mere reflection of a differ-
ence in lesion size. DAXX and ASK1 signaling was attenuated in
TAT.ARC-treated mice at 8 and 24 h after MCAo but not at 3 h
(Fig. 4A,B). A significant attenuation of activated BAX and
slightly decreased pJNK and pBIM proteins were detected at 8 or
24 h (Fig. 4B,C). Notably, phosphorylation of MAP44/42 kinase
was not altered at 3, 8, and 24 h of reperfusion in mice treated
with TAT.ARC or TAT.-Gal proteins (Fig. 4C).
TAT.ARC protein does not bind to activated JNK isoforms
To disentangle which JNK isoforms are phosphorylated after fo-
cal cerebral ischemia, immunoprecipitation experiments were
performed to immobilize phospho-JNK1-3 and then probe with
an antibody against all JNK isoforms (i.e., 1–3). JNK phosphor-
ylation was observed predominantly for JNK3, but JNK1 and
JNK2 were also activated in the TAT.-Gal-treated group (Fig.
5A). The exact ratio of activated isoforms cannot be predicted
because cross-reactivity of antibodies might be a confounder so
that proportions between activated isoforms might be a little dif-
ferent. In contrast to our recent results in the liver (An et al., 2012,
2013), activated endogenous JNK did not bind to exogenous
ARC protein in the brain (Fig. 5A,B). Notably, there was no
difference between the two groups in the lesion volumes of the
middle slice representing the core of the infarct at 24 h (Fig. 3A) as
analyzed by MRI.
We aimed to show that JNK phosphorylation is restricted to
the ischemic territory and performed immunoprecipitations
from brain lysates of the contralateral hemisphere of mice sub-
jected to MCAo and administration of TAT.-Gal or TAT.ARC
(Fig. 5B). In contrast to the ischemic territory, neither ARC bind-
ing nor phospho JNK signaling was detected in non-ischemic
tissue.
TAT.ARC directly interacts with DAXX and inhibits
recruitment to ASK1
We immunoprecipitated DAXX and blotted for ASK1 and phos-
phorylated ASK1 after treatment with TAT.-Gal or TAT.ARC
protein, respectively. Notably, coimmunoprecipitation was ob-
served as early as 3 and 8 h after reperfusion in TAT.-Gal-
treated animals but was below the threshold of the detection limit
in TAT.ARC transduced animals (Fig. 6A). At later time points
(24 h), interaction of DAXX and ASK1 was not detectable in
either group. DAXX immunoblotting confirmed the efficacy of
pull-down throughout all groups. Subsequently, we used immu-
noprecipitation to test whether or not endogenous and/or
exogenous ARC interacts with DAXX. Both exogenous and en-
dogenous ARC protein bound to DAXX and immobilized, as
indicated by immunoblotting the precipitates at 72 h after reper-
fusion in the contralateral hemisphere (Fig. 6B). No endogenous
ARC protein was detected in the ischemic hemisphere, and
DAXX–ARC binding was lower at this time point. Consequently,
we tested the earlier time points (3, 8, and 24 h) and immunopre-
cipitated both proteins (Fig. 6C). In line with the initiating com-
plex of DAXXwith ASK1 after 3 and 8 h of reperfusion (Fig. 6A),
an attenuated ARC–DAXX interaction was observed at these
time points in the ischemic hemisphere (Fig. 6C). Endogenous
ARC protein was diminished to under the threshold of detection
at 24 h (Fig. 6C). Furthermore, the interaction of ARC with
DAXX was completely abrogated in the mutant form of ARC
(L31F, G69R), with two point mutations in the CARD domain of
ARC, indicating CARD-dependent ARC–DAXX binding (Fig.
6D,E). Our data thus suggest that ARC interacts with DAXX
directly in a CARD-dependent manner and thereby inhibits
DAXX–ASK1 binding.
Delayed TAT.ARC administration protects the brain and
restores function
To test whether TAT.ARC administration is suitable as a neuro-
protectant against brain ischemia, we determined the therapeutic
window for delayed treatment. This is important for a clinically
relevant setting, in which spontaneous recanalization or throm-
bolysis might precede a therapeutic intervention and patients
have to be transported and diagnosed for ischemic brain injury.
We chose a higher dose of 5 g/mouse and a time point of 3 h
after onset of the MCAo (Fig. 7A). We subjected 15 mice per
4
(Figure legend continued.) shRNA delivery (shRNA) either nontargeting (shRNA-control) or
interferingwith ARCmRNA alongwith EGFP reporter expression and staining of dead cells with
PI (visualized in F). Knockdown of endogenous ARC was demonstrated by immunoblots (E).
Primary neuronal cultures were counterstained with PI for visualization of neuronal cell death
before and after 150min OGD (F,G). Normalized LDH release after ARC knockdown or best dose
of titration experiments for TAT proteins (D; 250 nM)wasmeasured 24 h after 150min OGD (H).
Data are presented as the mean normalized LDH release of four independent experiments and
presented asmean and scatter dot plots SEM. F[DFn, DFd](4,30) 13.84with p 0.0001 for
miR-shRNA or TAT treatment interactionwith OGD. F[DFn, DFd](4,30) 14.85with p 0.0001
for treatment effects and F[DFn, DFd](1,30)290.3withp0.0001 for OGDeffects. *p0.05
versus all other treatment groups within OGD; #p 0.05 versus all other treatment groups
except naive neurons within OGD.
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group to 60 min of MCAo. The mice were
tested and compared in the pole test for
their individual performance for time-to-
turn and time-to-descend as functional
outcome measures before and 48 h after
MCAo (Fig. 7B). Finally, mice were killed,
and the infarct volume was determined
histologically (Fig. 7C). Eight animals (of
30) were excluded from the analysis of the
pole test because they did not fulfill the
predefined criteria of a smooth run down
the pole (5 of 15 from TAT.-Gal and 3
animals from TAT.ARC). One animal (of
15) died after surgery before injection of
TAT.ARC protein. The animals in the
TAT.ARC group performed significantly bet-
ter inbothparameters andhad20% lower in-
farct volume than controls (Fig. 7B,C).
Delayed TAT.ARC administration
provides sustained neuroprotection
and functional benefits
To test whether TAT.ARC administration
provides sustained better long-term func-
tional recovery and neuroprotection, we
subjected 46 mice to either sham (n  8)
or 30minMCAo (n 15) surgery and 3 h
delayed treatment with TAT.-Gal or
TAT.ARC (Fig. 8).
Within the sham group, overall modi-
fiedDeSimoni neuroscore valueswere not
significantly different with -Gal than
with TAT.ARC (p  0.565). Within
MCAo mice, neuroscore values were sig-
nificantly lower with TAT.ARC than with
-Gal (p  0.015; Fig. 8B). Our first and
second hypotheses (general and focal def-
icit scores)were tested, and,withinMCAo
mice, both scores were significantly lower
with TAT.ARC thanwith-Gal (both p
0.022). Within the sham group, time on
the rotarod was not significantly differ-
ent (p  0.146) between -Gal- and
TAT.ARC-treated mice. In contrast,
withinMCAo, time on the rotarod was on
average 37 s shorter (p  0.033) with
Figure 2. Administration of TAT.ARC protein attenuates focal ischemic brain injury.A, Experimental setup ofMCAo, intrathecal
application of TAT proteins, and reperfusion time points for distinct analyses. B, Mice were subjected to 60 min MCAo, and TAT
proteins were administered intrathecally in the contralateral hemisphere during occlusion. Exogenous protein transduction with
TAT.-Gal or TAT.ARC was detected by immunoblots with the indicated antibodies and shows homogenous distribution of TAT
proteins throughout the brain after 72 h (brain lysateswere derived from2-mm-thick sagittal slices derived from subregions of the
ischemic and surrounding tissue of the ipsilateral hemisphere). C, Stability of TAT.-Gal or TAT.ARC proteins at indicated time
points after reperfusion derived from sham mice (3 h after delivery) or from the striatal ischemic core after 60 min of MCAo.
4
D, Representative MRI scan 72 h after 60 min MCAo showing
significantly attenuated brain injury in the TAT.ARC compared
with the TAT.-Gal-treatedmouse. E, Quantification of lesion
volume 24 and 72 h after 60 min MCAo. Data are presented as
mean and scattered dot plots SEM. T2 stroke volumeswere
analyzed by two-way RM ANOVA with F(1,43) 5.8 and p
0.03 for TAT treatment, F(1,43) 27.5 and p 0.001 for rep-
erfusion time point, and F(1,43)  4.5 with p  0.046 for
TAT  reperfusion time point interaction. F, Hematoxylin
staining after 72 h reperfusion time treated with TAT proteins
as indicated. G, Pole test, Data are presented as mean and
scattered dot plots SEM. Mann–Whitney U rank-sum test
for time-to-turn: T97.000n(small)11n(big)12 ( p
0.034); and time-to-descend: T  83.000 n(small)  11
n(big) 12 ( p 0.003).
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-Gal than with TAT-ARC. Mice within MCAo showed sus-
tained neuroprotective effects with longer time on the rotarod
after 14 d in the TAT.ARC cohort compared with TAT.-Gal-
treated mice (p  0.019, main hypothesis 3) with a time differ-
ence of on average 61 s longer on the rod [163.3 s (CI, 95–178) vs
197.1 s (CI, 170–225)]. MCAo mice had a steeper drop in body
weight (sham vs MCAo, p 0.002) that recovered in shammice
with TAT.-Gal after 13 d, in TAT.ARC in shammice after 5 d, in
MCAomice treatedwith TAT.ARC after 13 d, and inMCAomice
treated with TAT.-Gal after 20 d (Fig. 8F). Body temperature
was assessed non-invasively. We observed a pattern of fluctua-
tionswith a 7 d period but no significant difference between sham
versus MCAo mice (p 0.789).
Our hierarchical hypothesis 4 was an effect of TAT.ARC treat-
ment on histological parameters within MCAo. Striatal area was
measured inNeuN–DAB coronal slices as amarker for atrophy in
sham (n  3 animals per TAT.protein) and MCAo (n  14 for
TAT.-Gal and n  11 for TAT.ARC) mice. Mice within the
MCAo group that were treated with TAT.-Gal showed on aver-
age a steeper drop in striatal area on the ipsilesional hemisphere
than TAT.ARC-treated mice (2.9 mm2 in TAT.-Gal-treated vs
3.4 mm2 in TAT.ARC-treated mice, ipsilateral, p  0.067) that
was not significant. Neuronal densities were analyzed as a surro-
gate marker for residual stroke volume using coronal sections of
five regions from the frontal to the caudal pole of the brain (spe-
cific coordinates are described in Materials and Methods and in
the open dataset for Figs. 7C and 8K–M).
In summary, mean stroke volume after 28 d was slightly lower
withTAT.ARC treatment [7.3mm3 (CI, 4.7–9.8) vs 5.4mm3 (CI,
2.6–8.1), p 0.283; Fig. 8L]. We calculated the ipsilateral num-
ber of NeuN–DAB-positive cells in the striatum as a fraction to
the number of neurons on the contralesional side and found a
slight reduction of the ratios from 0.591 (CI, 0.455–0.728) to
0.701 (CI, 0.51–0.892; p 0.303; Fig. 8M). We were not able to
test our hypothesis 5 because our model of hierarchical testing
was underpowered to show a significant effect on striatal atrophy
(p  0.067) by TAT.ARC single post-stroke treatment in mice
with 28 d survival after 30 min MCAo. Nevertheless, we cannot
conclude that TAT.ARC treatment withinMCAohas no effect on
the number of neurons within the ipsilesional striatum and
Figure3. Administration of TAT.ARC protein attenuates focal ischemic brain injury in the cortical penumbra but attenuates cell death signaling independent of ischemic subregions.A, In analogy
to the biochemical analysis, ischemic hemisphereswere divided into 2mmsagittal slices for regional lesion volumeanalysis after 60minMCAo andquantified as described inMaterials andMethods.
Gray bar graphs indicate TAT.-Gal-treatedmice, and open bar graphs indicate TAT.ARC-treatedmice. Data are presented asmean and scattered dot plots SEM. T2 stroke volumeswere analyzed
by two separate mixed linear regression models with Sidak’s post hoc analysis. B–G, Immunoblots show blocked formation of cleaved caspase-8, caspase-9, caspase-3, and BAX activation (B, C),
reduced JNK activity (D, E), and blunted BIMphosphorylation (F,G) in response to TAT.ARC administration comparedwith TAT.-Gal-treatedmice. Different ischemic zones are shown as indicated.
Data are representative of three independent experiments (B,D, F). Mixed linear regressionmodels were applied for semiquantitative densitometricWestern blot analysis of three animals per TAT
protein group and presented as red scattered dot plots per animal and mean SEM. Quantification was referred to the indicated reference protein and the dilution factor of healthy tissue within
a subregion (characterized by T2 intensity in MRI) was used to adjust the Western blot signal to the lesion (for details, see Materials and Methods).
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stroke volume compared with TAT.-Gal-treatedmice 28 d after
MCAo.
Discussion
The results of the present study identify endogenous ARC as a
novel neuroprotective factor and hence a potential therapeutic
target after cerebral ischemia. Four major findings from cell cul-
ture and murine experimental stroke experiments support this
conclusion. First, we observed that endogenous ARC protein was
significantly downregulated as early as 20 h after 30minMCAoor
at 8 h after 60 min MCAo. This loss of neuronal ARC preceded
neuronal apoptosis, which occurred predominantly at 48 h and
reached amaximumat 72 h of reperfusion in thismodel (Katcha-
nov et al., 2001). ARC knockdown in primary neurons by RNA
interference resulted in higher susceptibility to cell death in re-
sponse to OGD compared with control shRNA. Conversely, ad-
ministration of exogenous ARC protein led to a dose-dependent
neuronal survival in response to OGD compared with TAT.-
Gal. Second, there is a significantly lower infarct size in
TAT.ARC-treated mice (30%) compared with TAT.-Gal-
treated controls after 60 min MCAo and 72 h of reperfusion.
Lower lesion volume after MCAo in TAT.ARC-treated mice was
associated with significantly better behavioral function when
compared with control animals. Third, we demonstrated that,
beyond inhibition of caspase activation and activation of proapo-
Figure 4. TAT.ARC-mediated inhibition of DAXX–ASK1–JNK signaling during focal ischemic infarction.A, Immunoblots demonstrate that TAT.ARC attenuates ischemia-induced activation of the
DAXX–ASK1–JNK signaling pathway at 24 h after ischemia compared with the corresponding area in TAT.-Gal-treated mice. The blots are representative of three independent experiments. B,
Semiquantitative analysis of immunoblots of three mice are presented as mean and scattered dot plots SEM. The right panel was adjusted to lesion volume as measured by T2 sequence in MRI
in the core slice after 24 h. DAXX, pASK1, and activated BAX showed significant TAT treatment time interactions as analyzed by two-way ANOVA, followed by Tukey’s post hoc analysis. pJNK1-3
showed significant treatment ( p0.03) and time ( p0.0002) effects butno interaction ( p0.0988). pBimshowedno significant treatment time interaction ( p0.065).Post hoc testswere
significant as indicatedby asterisks between TAT-Gal and TAT.ARC comparisons per timepoint in the graphs.C, Immunoblots shownoeffects onMAP44/42 kinase pathway in response to TAT.ARC
administration compared with TAT.-Gal-treated mice. Different reperfusion times from the middle ischemic slice are shown as indicated. Data are representative of three independent
experiments.
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ptotic BH3-only proteins BAX andBIMbyARC,ARC also blocks
DAXX–ASK1–JNK-mediated cell death via direct interaction
with DAXX. The specificity of these findings was demonstrated
by the absence of an effect on the MAP44/42 kinase pathway.
Finally, we provided evidence that TAT.ARC could be adminis-
tered as late as 3 h after the onset of ischemia/reperfusion injury
and still provided significant neuroprotective functional benefits
for brain protection in a 60minMCAomodel with 3 d and in a 30
min MCAo with 28 d survival. Together, these observations sug-
gest that ARC plays a crucial role during the ischemic stress
response in the brain by providing early antiapoptotic neuropro-
tective signals that promote neuronal survival, minimize tissue
injury, and preserve behavioral performance. Previous studies
showed that ASK1–JNK signaling plays a crucial role during cell
death (Chang et al., 1998). Recently, more attention has been
paid to the connection between DAXX and ASK1–JNK signaling
(Karunakaran et al., 2007; Ryo et al., 2007). Besides the activation
of downstream targets of death signaling, such as caspase-8,
caspase-9, caspase-3, or BAX and BIM, activation of key up-
stream death mediators, such as DAXX, ASK1, and JNK, were
detected afterMCAo. Importantly, research has shown that, after
exogenous ARC administration, activation of both upstream and
downstream death mediators is substantially suppressed com-
pared with levels in mice treated with TAT.-Gal during late
reperfusion. We showed that exogenous ARC interferes with
DAXX–ASK1–JNK-mediated death signaling and neuronal cell
loss afterMCAo by directly bindingDAXX. ARC–DAXXbinding
is specific, dependent on the CARD domain of ARC, and inde-
pendent of neuronal injury. The absence of a CARD and death
domain inDAXX suggests other nonhomotypic death-fold inter-
actions between DAXX and ARC. Additional studies will aim to
map the ARC binding domain in DAXX.
TheDaxx gene encodes a multifunctional protein that resides
in many locations, such as the nucleus and cytoplasm, and func-
tions as a transcriptional regulator. Previous studies suggest that
DAXX has both proapoptotic and antiapoptotic functions, de-
pending on its subcellular localization and concentration (Niu et
al., 2011). DAXX promotes cell death and JNK activation under
physiological conditions (Khelifi et al., 2005). DAXX-depleted
cells are resistant to cell killing induced by ultraviolet irradiation
and oxidative stress after impaired ASK1–JNK activation (Khelifi
et al., 2005). DAXX overexpression sensitizes cells not only to
FAS-induced apoptosis but also to TGF-induced JNK activa-
tion (Perlman et al., 2001). Oxidative stress can trigger DAXX
induction and induce neuronal cell death, both of which can be
inhibited by antioxidant treatment (Niu et al., 2011). Activated,
cytoplasmic DAXX binds to and activates ASK1 and triggers ac-
tivation of MKK4/7–JNK (Yang et al., 1997; Chang et al., 1998;
Song and Lee, 2003; Khelifi et al., 2005; Rodriguez-Nieto and
Zhivotovsky, 2006; Niu et al., 2011). DAXX was reported to pro-
mote ASK1-mediated apoptosis in a kinase- and caspase-
independent manner (Charette et al., 2001). By blocking DAXX
trafficking, rat hippocampus CA1 neurons were protected
against cerebral ischemia/reperfusion injury (Niu et al., 2011).
InterferingwithDAXX signaling decreasedASK1 activation, sup-
pressed the assembly of the FAS–DAXX–ASK1 signalingmodule,
and subsequently inhibited JNK activation and c-Jun phosphor-
ylation (Niu et al., 2011). Furthermore, knockdown of endoge-
nous DAXX exerted similar neuroprotective effects during
ischemia/reperfusion (Niu et al., 2011).
Recent evidence suggests that activation of JNK signaling
plays a crucial role in ischemia-induced neuronal death (Kuan et
al., 2003; Guan et al., 2005, 2006a,b). Here, we did not show that
ARC directly binds JNK1/2 in a tissue-dependent manner and
thereby inhibits JNK activation (An et al., 2012). This argues
against a direct effect of ARC on JNK signaling in the brain and
might explain why substantial JNK activation was detected at 3 h
of reperfusion even in the ARC-treated group. In fact, ARC bind-
ing mediated the inhibition of DAXX activation, and ASK1–JNK
signaling prevents sustained JNK activation, as seen in the
TAT.-Gal groupwith subsequent caspase activation and neuro-
nal cell death. Consistent with our findings, others show that
inhibition of nuclear export of DAXX prevents JNK activation
(Jung et al., 2007).
One major therapeutic advantage of ARC-mediated neuro-
protection is the fact that it affects many pathways, whereas most
antiapoptotic approaches only operate selectively, interfering
with either death receptor only or mitochondrial apoptotic sig-
naling only. Others operate only at the postmitochondrial level,
as with caspase inhibitors. The multimodal pleiotropic death-
repressing interactions of exogenous ARC protein with key initi-
ators (such as DAXX) of both death pathways suggests that
TAT.ARC might be a more powerful tool for stroke treatment
than are caspase or small-molecule JNK inhibitors, which target
only one pathway (see proposedmodel ofmolecularmechanisms
in Fig. 7D). We observed a robust and significantly lower lesion
volumes of 30% compared with controls and a preserved func-
tion of behavior when TAT.ARC was applied during occlusion.
Figure 5. TAT.ARC treatment inhibits JNK phosphorylation after focal brain ischemia. A,
Whole-brain lysates from damaged or corresponding contralateral zone 72 h after ischemia or
sham operation treated with TAT.ARC or TAT.-Gal were immunoprecipitated with an anti-
phospho-JNK antibody and then immunoreacted as indicated. Brain lysate plus Protein A or G:
Plus-Sepharose beads without anti-pJNK or lysate plus anti-pJNK antibody without beads
served as internal loading controls. B, Higher phospho-JNK signals were not detected in the
contralateral hemisphere ofmice subjected to focal brain ischemia and treatedwith TAT.-Gal
or TAT.ARCproteins.Whole-brain lysates fromshammice or contralateral to the ischemic hemi-
sphere were immunoprecipitated with anti-phospho-JNK antibody and detected by Western
blots as indicated.
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Figure 6. ARC interacts with DAXX and prevents DAXX–ASK1 binding. A, Exogenous ARC
prevents DAXX–ASK1 binding. Brain extracts from the middle slice of the reperfusion or corre-
sponding contralateral slicewere immunoprecipitated using anti-DAXX antibody. Immunopre-
cipitates were immunoblotted for DAXX and ASK1, respectively. Brain lysates of the middle
4
slices plus beads without anti-DAXX antibody served as internal loading controls. B, ARC binds
DAXX in the cerebral cortex under physiological and ischemic conditions 72 h after reperfusion.
Brain homogenates of themiddle slices were immunoprecipitated with anti-ARC antibody and
immunoblotted with antibodies against DAXX, ARC, and HA. Brain lysate plus beads without
anti-ARC or lysate plus anti-ARC antibodywithout beads served as controls. C, Endogenous and
exogenous ARC interacts with endogenous DAXX in vivo. Immunoprecipitation of brain lysates
of the middle slice after ischemia or sham operation were performed with anti-ARC or anti-
DAXX as primary antibodies. Brain lysates plus beads without anti-ARC or anti-DAXX antibody
served as controls. D, Domain structures of TAT proteins with their tags and mutations. His,
Histidin tag; HA, hemagglutinin tag; P/E-rich, proline/glutamate rich domain;-Gal,-galac-
tosidase; L, leucine; F, phenylalanine; G, glycine; R, arginine. E, ARC interacts via its CARD
domain with DAXX. Brains were transduced with TAT.-Gal, TAT.ARC, or TAT.ARC.mutant
(L31F; G69R) and immunoprecipitatedwith anti-DAXX antibody. Immunoblots were probed as
indicated and derived from twomice and replicated in triplicate.
Figure 7. Delayed administration of TAT.ARC protein attenuates focal ischemic brain injury.
A, Experimental setup of MCAo, intrathecal application of TAT proteins, and reperfusion time
points for distinct analyses. B, Pole test, Data are presented as the increase of time to turn and
time to descend after MCAo compared with individual performance in mice before ischemia.
Data are presented as mean and scattered dot plots SEM; n 10 and n 11 animals
(TAT.-Gal vs TAT.ARC). For specific exclusion criteria andmortality, seeMaterials andMethods
and Results. C, Indirect infarct size was measured using hematoxylin staining after 72 h as
described inMaterials andMethods. Data arepresentedasmeanand scattereddot plotsSEM
with n 15 animals in TAT.-Gal and n 14 animals in the TAT.ARC group. D, Proposed
model of molecular mechanisms of TAT.ARC treatment targeting the penumbra after brain
ischemia.
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This effect was not as strong but still present (20% lower com-
pared with controls) if treatment was delayed to 3 h after onset of
ischemia, and it still was associated with better behavioral out-
come than in controls. This reduction of effect size fits the well
known “time is brain” concept for recanalization in humans.
Subregions of the ischemic territory as analyzed in Figure 3model
the tissue at risk in the lateral or inner penumbra. This region
includes the cortex and medial striatum. The core of the infarct
Figure 8. Delayed administration of TAT.ARC protein attenuates focal ischemic brain injury and fosters recovery in the long term. A, Experimental setup of MCAo, 3 h delayed intrathecal
application of 5g of TAT proteins, and reperfusion time points for distinct analyses. Compositemodified DeSimoni neuroscore (B) with general (C) and focal deficit (D) scores and rotarod data (E,
F). Rotarod data after 14 d is shown as the mean time on the rod with CIs. G, Body weight was measured before surgery (day 0) and after non-invasive transponder-mediated body temperature
measurements (H). Data inB–D andG,H are presented asmean SEM and in F, L, andM asmean CI. I, Multiple image alignment of neuronal staining using anti-NeuN–DAB of shammice and
28 d after MCAo (J). Striatal area in coronal section a3 (K) in both ipsilateral and contralateral hemispheres and residual infarct area/scar as defined by decreased neuronal density (L) and ratios of
ipsilesional versus contralesional neurons counted in TAT.-Gal or TAT.ARCmice (M) were illustrated by scatter dot plots and box andwhiskers (minimum tomaximum) forK andmean CI (L,M).
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compromised the lateral striatum. The percentage of salvaged
tissue cross-sectionally increases from 30 to 41% in the lateral
and in the inner penumbra to even 54% because it is amenable to
rescue whereas, as expected, the ischemic core shows the modest
cross-sectional reduction of 22% if TAT.ARC is applied during
occlusion (Fig. 3A).
Finally, we studied the effect of a single, delayed injection of
TAT.ARCprotein and compared it with TAT.-Gal-treatedmice
subjected to sham/MCAo and used hierarchical testing of hy-
potheses: most important were better outcome (first three hy-
potheses) and effect on striatal atrophy and neuronal cell death in
the striatum (hypotheses 4 and 5) after 28 d. We were able to
show sustained effects on better outcome of a single dose of TAT
protein applied 3 h after the onset of ischemia (Fig. 8). Indepen-
dent functional parameters of TAT.ARC-dependent effects on
recovery were the general and focal deficits and longer time on
the rotarod of TAT.ARC-treated mice compared with TAT.-
Gal-treated controls. Striatal atrophy after stroke was cross-
sectionally reduced 28 d after MCAo but not significantly (p 
0.067 for atrophy reduction by TAT.ARC treatment). At this
level, hypothesis testing terminated by a priori definition. Our
studywasmost likely underpowered for effects on loss of neurons
within the striatum in the long term. We are confident that the
effect sizes in our study are robust, because great emphasis was
put on internal validity (reduction of bias) and conformity to
ARRIVE reporting guidelines and conducted in a laboratory with
certified qualitymanagement. TAT.ARC protein transduction or
ARC-related small molecules could be of therapeutic benefit for
preventing and treating ischemic brain injury in humans along
with treatment modalities aiming for reperfusion. This might
buy time for the brain and preserve its function. In summary, the
strength of this study is the identification of a novel endogenous
neuroprotectivemolecularmechanism and the proof of principle
that each treatment starting during occlusion or applied after
reperfusion with TAT.ARC is neuroprotective after experimental
stroke. Our study warrants additional confirmatory preclinical
studies for detailed dose–response curves, comorbidity effects,
gender studies, and interference with the only available therapy,
that is, thrombolysis or endovascular thrombectomy. A limita-
tion of this study is the application route of TAT proteins.
TAT.Bcl-x(L), TAT.Hsp70, and TAT.GDNF have been given in-
travenously after MCAo (Kilic et al., 2003; Doeppner et al.,
2009a,b). This needs to be addressed in future studies andwas not
within the scope of this mechanistic explorative approach (Kim-
melman et al., 2014).
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